前收市價 | 8.88 |
開市 | 8.89 |
買盤 | 8.80 x 100 |
賣出價 | 8.82 x 100 |
今日波幅 | 8.80 - 9.05 |
52 週波幅 | 6.57 - 22.93 |
成交量 | |
平均成交量 | 1,292,843 |
市值 | 838.93M |
Beta 值 (5 年,每月) | 0.95 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | -2.00 |
業績公佈日 | 2024年5月02日 - 2024年5月06日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 31.89 |
In this article, we’re going to take a look at 13 best biotech stocks to buy under $20. To see more stocks that made the list, you can skip ahead and jump straight to the top 5 best biotech stocks to buy under $20. When it comes to investing, few industries are as exciting to […]
Akero (AKRO) reports positive results from its mid-stage study of efruxifermin in pre-cirrhotic metabolic dysfunction-associated steatohepatitis patients at week 96. The stock gains 12%.
The average of price targets set by Wall Street analysts indicates a potential upside of 121.5% in 89BIO (ETNB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.